Stock Analysis

Panaxia Labs Israel Full Year 2022 Earnings: ₪0.29 loss per share (vs ₪1.52 loss in FY 2021)

Source: Shutterstock

Panaxia Labs Israel (TLV:PNAX) Full Year 2022 Results

Key Financial Results

  • Revenue: ₪39.4m (down 53% from FY 2021).
  • Net loss: ₪43.3m (loss widened by 102% from FY 2021).
  • ₪0.29 loss per share.
TASE:PNAX Earnings and Revenue History March 25th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Panaxia Labs Israel's share price is broadly unchanged from a week ago.

Risk Analysis

Before you take the next step you should know about the 6 warning signs for Panaxia Labs Israel (4 are potentially serious!) that we have uncovered.

Valuation is complex, but we're helping make it simple.

Find out whether Panaxia Labs Israel is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis